Cross-Sector entity
Every one of those 1 sits in a single category, clinical-trial. Polaryx is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. Polaryx appears in 1 tracked Cross-Sector story from February 18, 2026. The tracked stories average 28 original sources each.
1 verified story tracked
Last mentioned: Feb 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Polaryx is most often covered alongside Bayer Aktiengesellschaft, which appears in 1 of these 1 story. Polaryx appears in 1 tracked Cross-Sector story from February 18, 2026. The tracked stories average 28 original sources each.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Polaryx. Shared-story counts are live from our verified record — not editorial picks.
Genmab A/S reported a decline in full-year profits, marking a period of significant financial and clinical divergence across the biotechnology sector. While breakthrough results in depression therapy propelled Compass Pathways, Ocular Therapeutix suffered a sharp decline despite meeting Phase 3 trial endpoints.
